CBA Biotech Committee & OBA Information Technology and Intellectual Property LAW PROGRAM | Original Program Date: December 7, 2017

Regulation under the Patented Medicine Prices Review Board (PMPRB) is a key concern for pharmaceutical companies. With major changes likely coming, ensure you are up to speed on the latest developments and have the expertise you need to advise your pharmaceutical clients with this helpful program. Join us to explore the current landscape and future direction of the PMPRB, including modernization initiatives and Health Canada’s consultations. Our expert faculty will share valuable insights and best practices for engaging with the PMPRB to help you enhance your practice.

To view the full program agenda, please click here.

PROGRAM CHAIRS

Geoff Mowatt, DLA Piper (Canada) LLP
Tracey Stott, Norton Rose Fulbright Canada LLP

PROGRAM SPEAKERS

Jill Daley, Eli Lilly Canada Inc.
Neil Fineberg, Partner, Fineberg.Legal LLP 
Matthew Kellison, Director, Regulatory Affairs & Outreach, PMPRB
Neil Palmer, Founder & Principal Consultant, PDCI Market Access Inc
Kristin Wall, Partner, Norton Rose Fulbright LLP